Weill Cornell Genitourinary Cancer Program

Home
United States
New York, NY
Weill Cornell Genitourinary Cancer Program

World-class care for prostate, kidney, bladder, testicular and other genitourinary (GU) cancers.

02/23/2026

Part 5 of the GU Oncology Now discussion on clonal hematopoiesis in the field of dives into how treatment intensity, timing, and monitoring might limit clonal expansion in select patients. Watch Dr. Scott Tagawa and Dr. Pinkal Desai explain:

This is a 429 error. Try accessing this page directly or wait a few minutes and try again. Everyone has their limits, and we're getting too many requests right now.

02/19/2026

Healthcare professionals: Dr. Scott Tagawa is speaking at an adjunct symposium during American Society of Clinical Oncology on 2/27. Register for in-person or virtual participation to learn about the treatment landscape of metastatic hormone-sensitive .

Join us for a dynamic live symposium held adjunct to the 2026 ASCO® Genitourinary Cancers Symposium where two nationally recognized experts will...

02/17/2026

In the next part of the GU Oncology Now discussion on clonal hematopoiesis in the field of , Dr. Scott Tagawa and Dr. Pinkal Desai discuss clinical implications in the era of PSMA-targeted therapies:

This is a 429 error. Try accessing this page directly or wait a few minutes and try again. Everyone has their limits, and we're getting too many requests right now.

01/29/2026

Learn more about how baseline clonal hematopoiesis may be able to predict toxicity from targeted radionuclide therapy for patients in part 3 of this GU Oncology Now discussion featuring Dr. Scott Tagawa and Dr. Pinkal Desai:

Dr. Desai distinguishes aging-related versus therapy-related CH and shows that preexisting CH drives clonal expansion and hematologic toxicity during PSMA-targeted RLT.

01/26/2026

In part 2 of the GU Oncology Now discussion on clonal hematopoiesis in the field of , Dr. Scott Tagawa and Dr. Pinkal Desai discuss tracking clonal hematopoiesis over time in patients treated with Lu-PSMA-617:

The panelists review real-world and institutional data showing that clonal hematopoiesis is common during lutetium PSMA-617 therapy.

01/23/2026

GU Oncology Now gathered an expert panel including Dr. Scott Tagawa and Dr. Pinkal Desai of Weill Cornell Leukemia Program to discuss clonal hematopoiesis in the field of :

Dr. Desai distinguishes aging-related versus therapy-related CH and shows that preexisting CH drives clonal expansion and hematologic toxicity during PSMA-targeted RLT.

01/19/2026

Hear more from Dr. Jim Hu about a new posterior approach to nerve-sparing prostatectomy for patients via Urology Times:

Jim C. Hu, MD, MPH, discusses the functional advantages of a posterior approach to endopelvic neurovascular total sparing (PATENTS) robotic-assisted radical prostatectomy.

12/19/2025

Watch Dr. Scott Tagawa talk to GU Oncology Now about the PSMAddition trial which evaluated intensifying treatment earlier in patients with :

Dr. Tagawa provides the latest clinical update from PSMAddition and relevancy for community and academic practitioners alike.

11/26/2025

At , Dr. Scott Tagawa spoke with OncLive about the rapidly changing treatment landscape for and :

Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.

11/24/2025

Learn more about the differences between androgen receptor pathway inhibitors (ARPIs) and androgen deprivation therapy (ADT) combinations for metastatic hormone-sensitive from Dr. Cora Sternberg:

During a live event, Cora N. Sternberg, MD, discussed tolerability outcomes from the ARANOTE trial and distinguishing aspects of androgen receptor pathway inhibitors.

11/15/2025

Hear Dr. Scott Tagawa’s interview with Oncology Learning Network about the results he presented at and the potential future of the therapy:

Scott Tagawa, MD, Weill Cornell Medicine, discusses results from the phase 3 PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to androgen deprivation therapy and androgen receptor pathway inhibitor therapy for patients with metastatic hormone-sensitive prostate cancer.

11/12/2025

Dr. Cora Sternberg spoke with Targeted Oncology about the evolution of combination therapies for metastatic hormone-sensitive :

During a live event, Cora N. Sternberg, MD, discussed the development of androgen receptor pathway inhibitors and takeaways from the ARANOTE trial in hormone-sensitive prostate cancer.

Address

520 East 70th Street, Starr Pavilion, 3rd Floor
New York, NY
10065

Website

http://www.weillcornellgucancer.org/

Alerts

Be the first to know and let us send you an email when Weill Cornell Genitourinary Cancer Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Featured

Magnus Wellness
16 E 40th Street, Fl 4

Want your practice to be the top-listed Clinic in New York?

Who We Are

The Genitourinary (GU) Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital provides world-class clinical care. We are at the forefront of scientific research and clinical trials, enabling us to provide a full range of diagnostic and treatment protocols, including the latest breakthroughs in medicine. We view each patient as an individual, and use a multidisciplinary approach to ensure that each treatment regimen is narrowly tailored to meet the unique needs of the patient and his or her diagnosis. Learn more by visiting www.weillcornell.org/gucancer